This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP eLearning Days 2022.
Program Description
Women with advanced or recurrent endometrial cancer experience poor prognosis and a 5-year survival rate of just 17%. Clinical efficacy and safety data supporting use of immune checkpoint inhibitor-based therapies and combination therapy regimens have demonstrated increased benefit for patients with endometrial cancer, and current guidelines recommend treatment initiation with novel target-specific and immunotherapeutic approaches for patients with high-risk disease. Managed care professionals can be instrumental in promoting appropriate utilization of biomarker testing, helping to guide cost-effective treatment selection for patients with endometrial cancer. This activity will review recommendations on the use of biomarker testing in determining evidence-based treatment for patients whose disease has progressed despite therapy. Considerations for management of immune-related toxicities as well as costs and strategies to treat these adverse effects will also be discussed.
Target audience: Health-system, managed care, oncology, and specialty pharmacists
Type of activity: Application
Release date: May 18, 2022
Expiration date: May 18, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Demonstrate understanding of the epidemiology of endometrial cancer and the role of biomarkers in guiding treatment with novel therapies
- Determine the guideline-recommended role of molecularly targeted and immune-based therapies in the management of endometrial cancer
- Apply the evidence regarding cost of care and cost-effectiveness of novel immunotherapy in the treatment of endometrial cancer
Allison Baxley, PharmD, BCOP
Assistant Vice President, Oncology and Ambulatory Care Pharmacy
Department of Pharmacy
OU Health
Oklahoma City, Oklahoma
Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-256-H01-P. The activity is available for CE credit through May 18, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Allison Baxley, PharmD, BCOP, and Laura R. Bobolts, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms